The first Oral Abstract sessions open on Wednesday, Feb. 4, and will continue each day at the 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT^® and CIBMTR^®.

Collectively, these 14 Scientific Track Oral Abstract sessions and the additional track-specific abstract sessions provide the opportunity to hear directly from authors of more than 100 of the most impactful research papers of the past and current year in the field of transplantation, cell and gene therapy. 

“I think oral abstract sessions are one of the many highlights of the Tandem Meetings,” said Scientific Organizing Committee (SOC) Co-Chair Betty Hamilton, MD. “Oral abstracts can allow attendees to hear the latest research advances in the field, often before full publication, helping the dissemination of novel or high-impact data. It also gives researchers the opportunity to present more preliminary findings, fostering robust scientific dialogue between presenters and attendees. Works presented in abstracts at the meeting often shape the scientific narrative of the current and future meetings.”

Best Abstracts

Six papers have been selected for presentation and discussion at the Welcome, Awards & Best Abstracts session on Friday, Feb. 6, from 8:15 – 10:00 a.m. MST.

They represent a range of relevant and cutting-edge themes, from Clinical Outcomes from the Pooled Safety Analysis of CD19 Nex-T™ (BMS-986353), a Chimeric Antigen Receptor (CAR) T cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results from Phase 1 Breakfree Studies (presented by Ran Reshef, MD, MSc) to Remodeling the Multiple Myeloma Bone Marrow Microenvironment with CART Cells to Overcome Resistance (presented by Jennifer Feigin, PhD candidate).

Scientific Track Oral Abstracts

During the 2026 Tandem Meetings, more than 80 papers will be discussed in 14 different Scientific Track Oral Abstract sessions.

First-day oral abstract sessions include presentations on clinical developments in graft-versus-host disease (GVHD), mitigating toxicities in CAR-T therapy, hemoglobinopathy and social determinants of health, all at 3:15 – 4:45 p.m. MST.

Of the first-day oral abstracts, Dr. Hamilton highlighted Session D – Social Drivers, Access Challenges, and Equity in Transplant and Cellular Therapy Care Delivery. She said this session explains how the field can advance only if researchers and clinicians continue to optimize access and equity.

 “This is an incredibly important topic essential to our therapies. While it is incredibly exciting how many advances there have been in transplant and cell therapy, our treatments are only as good as our ability to deliver them,” she said. “This is particularly important given that transplant/cell therapy can be resource-intensive.”

The full list of Scientific Track Oral Abstract sessions includes these sessions (all times listed below are MST):

Wednesday, Feb. 4, 3:15 – 4:45 p.m.

• Oral Abstract – Session A – Clinical Progress in GVHD Prevention, Risk Stratification, and Treatment, Ballroom AB
• Oral Abstract – Session B – Identifying and Mitigating Toxicities to Enhance CART Safety, Ballroom I
• Oral Abstract – Session C – Hemoglobinopathy: Novel Gene Therapy and Transplant Strategies, Ballroom J
• Oral Abstract – Session D – Social Drivers, Access Challenges, and Equity in Transplant and Cellular Therapy Care Delivery, Room 254 A-C

Thursday, Feb. 5, 3:15 – 4:45 p.m.

• Oral Abstract – Session E – Acute Lymphoid Leukemias: Advances in CAR T and Transplant Approaches, Ballroom AB
• Oral Abstract – Session F – Multiple Myeloma: Advances in CAR T and Transplant Approaches, Ballroom I
• Oral Abstract – Session G – Transplantation and Cellular Therapy for Autoimmune Disease, Immune Deficiencies, and Solid Organ Malignancies, Ballroom J
• Oral Abstract – Session H – Emerging Cellular and Molecular Drivers of GVHD Pathogenesis, Room 254 A-C

Friday, Feb. 6, 3:15 – 4:45 p.m.

• Oral Abstract – Session I – CAR T Effectiveness, Durability, and Real-World Outcomes in Lymphoma, Ballroom AB
• Oral Abstract – Session J – Conditioning and Risk Stratification for AML, MDS, and Myelofibrosis, Ballroom I
• Oral Abstract – Session K – Improving Survivorship, Symptom Burden, and Quality of Life After Transplantation, Ballroom J

Saturday, Feb. 7, 10:30 a.m. – 12:00 p.m. 

• Oral Abstract – Session L – Innovations in CAR T Engineering and Cellular Therapies for B-Cell Malignancies, Ballroom AB
• Oral Abstract – Session M – Conditioning Regimens and Early Toxicities Across Pediatric and Adult Transplantation, Ballroom I
• Oral Abstract – Session N – Allogeneic Transplantation: Donor Biology, Immune Regulation, and GVHD Risk Reduction, Ballroom J

Track-Specific Abstract and Oral Abstract Sessions

In addition to the general Scientific Track, several of the program tracks hold abstract sessions that will focus on influential research within their sub-field. All times listed below are MST.

Wednesday, Feb. 4

• Infectious Diseases: Top 3 Abstracts, 1:45 – 2:30 p.m., Room 251 A-F
• CRPDM: CRPDM Oral Abstract Presentations, 2:00 – 3:00 p.m., Room 250 A-F

Thursday, Feb. 5

• IT and Informatics: Center Abstracts / Case Studies, 11:00 a.m. – 12:00 p.m., Room 250 A-F
• APP: Best Abstracts Session, 1:00 – 1:45 p.m., Room 251 A-F
• Pediatric: Pediatric Best Abstracts, 3:30 – 5:30 p.m., Room 155 A-G

Friday, Feb. 6

• Nursing: Best Abstracts, 10:30 – 11:15 a.m., Room 255 A-G
• Pharmacy: Best Abstracts, 2:00 – 3:00 p.m., Room 250 A-F
• Nursing: Oral Abstracts: Patient Care, 2:15 – 3:00 p.m., Room 255 A-G
• Nursing: Oral Abstracts: Psychosocial Patient Support, 4:30 – 5:00 p.m., Room 255 A-G

Saturday, Feb. 7

• Administrative Director: Best Abstracts, 9:00 – 10:00 a.m., Room 155 A-G
• Nursing: Oral Abstracts: Nursing Support, 9:15 – 10:00 a.m., Room 255 A-G